AbbVie 향후 성장
Future 기준 점검 4/6
AbbVie (는) 각각 연간 25.2% 및 6.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 26.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 228.1% 로 예상됩니다.
핵심 정보
25.2%
이익 성장률
26.37%
EPS 성장률
| Biotechs 이익 성장 | 25.5% |
| 매출 성장률 | 6.3% |
| 향후 자기자본이익률 | 228.15% |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 19 May 2026 |
최근 향후 성장 업데이트
Recent updates
분석 기사 • May 15
We Think You Can Look Beyond AbbVie's (NYSE:ABBV) Lackluster Earnings
The market was pleased with the recent earnings report from AbbVie Inc. ( NYSE:ABBV ), despite the profit numbers being...Seeking Alpha • May 11
AbbVie Q1: Skyrizi Delivers, Here's What Skeptics Are Missing
Summary AbbVie (ABBV) delivered strong Q1 2026 results, with $15B revenue (+12.4% YoY) and Skyrizi sales up 30.9%, prompting raised EPS guidance. Despite analyst concerns over new oral competitors like Icotyde, Skyrizi maintains a clear efficacy advantage and expanding indications, supporting robust growth. ABBV is trading at 14.2x 2026 EPS with a 0.84x PEG, offering compelling value amid 17% projected earnings growth and a $250/share price target. Risks include pricing pressures, high product concentration, and pipeline execution, but current market skepticism creates a classic wall of worry opportunity. Read the full article on Seeking Alpha
내러티브 업데이트 • Apr 23
ABBV: Future Returns Will Rely On Immunology Expansion And Operating Leverage Execution
Analysts made a small upward adjustment to AbbVie’s fair value estimate to about $249. The modest change reflects a mix of slightly higher assumed discount rates and future P/E multiples, alongside recent shifts in Street price targets, including both raises and trims from firms such as Piper Sandler, Guggenheim, Cantor Fitzgerald, Evercore ISI, Citi and UBS, as well as fresh bullish initiations from Canaccord, RBC Capital and Barclays.내러티브 업데이트 • Apr 08
ABBV: Future Returns Will Hinge On Immunology Encore And Operating Leverage Execution
Analysts have made a modest upward adjustment to AbbVie’s price target, reflecting updated views on its immunology pipeline potential, operating leverage, and the ongoing debate about whether recent share underperformance and selloffs adequately reflect competitive risks. Analyst Commentary Recent research on AbbVie highlights a split view, with some analysts focusing on the upside from the immunology pipeline and operating leverage, while others point to valuation and competitive questions after a period of share underperformance.내러티브 업데이트 • Mar 24
ABBV: Future Returns Will Hinge On Immunology Encore Outweighing Competitive Concerns
Narrative Update The analyst price target for AbbVie has been adjusted slightly higher to reflect a fair value move to about $249. Analysts point to early stage indication expansion, operating leverage potential, and ongoing immunology pipeline developments, even as some firms flag emerging competition and a more balanced risk and reward profile.내러티브 업데이트 • Mar 10
ABBV: Future Returns Will Depend On Immunology Encore And Deal Optionality Uncertainty
The analyst price target for AbbVie edges higher to align with our fair value shift from $248.29 to $248.86, as analysts highlight ongoing indication expansion in immunology, potential operating leverage, and multiple expansion drivers, even as some firms note emerging competition and a more balanced risk and reward profile. Analyst Commentary Recent research on AbbVie reflects a split view, with some analysts pointing to upside tied to immunology growth and pipeline execution, while others flag competition risk and a more balanced risk and reward profile at current levels.
새로운 내러티브 • Mar 01
AbbVie Inc. (ABBV): The Immunology Powerhouse – Successfully Navigating the Post-Humira Transition
AbbVie (ABBV) has entered 2026 as a masterclass in pharmaceutical "lifecycle management," having effectively neutralized the long-feared "patent cliff" of its flagship drug, Humira. As of the February 27, 2026 close, the stock is trading at $232.03 , following a robust 3.3% single-day gain that capped off a volatile but ultimately bullish month.내러티브 업데이트 • Feb 22
ABBV: Future Returns Will Rely On Immunology Encore And Evolving Deal Optionality
Our updated AbbVie narrative reflects a modest price target increase to about $248 per share, as analysts point to potential operating leverage, room for P/E multiple expansion, and a pipeline of proof-of-concept and immunology programs that could support slightly higher revenue growth assumptions, even as margin expectations are trimmed. Analyst Commentary Recent research shows a mix of optimism and caution around AbbVie, with several firms adjusting price targets and ratings as they reassess execution risks, competitive pressures, and the potential impact of the pipeline on valuation.내러티브 업데이트 • Feb 07
ABBV: Future Returns Will Depend On Immunology Pipeline Clarity And M&A Uncertainty
Analysts have trimmed their price targets for AbbVie by a small amount. This reflects slightly lower revenue growth and P/E assumptions, while also incorporating a modestly higher profit margin and recent mixed research views around competition and pipeline visibility.내러티브 업데이트 • Jan 24
ABBV: Future Returns Will Hinge On Post-Humira Immunology And Deal Optionality
Analysts have nudged their price target for AbbVie slightly higher to reflect a fair value estimate of about $245 per share, supported by updated assumptions for revenue growth, profit margins, and a modestly lower future P/E. Recent research highlights both increased price targets and more cautious views around competition and the sustainability of outperformance in key immunology drugs.내러티브 업데이트 • Jan 09
ABBV: Future Returns Will Depend On Post-Humira Immunology And Pipeline Execution
Analysts have trimmed their AbbVie fair value estimate by about $0.10 per share to roughly $244.56. This reflects a mix of slightly higher risk assumptions, modestly adjusted revenue and margin expectations, and a more balanced set of views after recent downgrades and price target changes that suggest outperformance is already well reflected in the current share price.분석 기사 • Jan 08
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 17th of February to...내러티브 업데이트 • Dec 21
ABBV: Future Returns Will Hinge On Post-Humira Immunology And Pipeline Execution
Analysts have nudged our AbbVie fair value estimate slightly higher, from $243.55 to $244.68. This reflects modestly stronger long term revenue growth expectations for key immunology franchises and pipeline assets, partially offset by slightly lower margin assumptions and a broadly constructive but mixed backdrop of recent price target revisions and rating changes across the Street.내러티브 업데이트 • Dec 07
ABBV: Future Performance Will Depend On Extended Exclusivity And Pipeline Execution
Analysts have nudged their average price target on AbbVie modestly higher to reflect a wave of target increases into the mid 240s to low 260s dollar range, supported by stronger visibility into Skyrizi and Rinvoq driven growth, extended Rinvoq exclusivity, and a more favorable large cap biopharma backdrop despite mixed ratings changes. Analyst Commentary Recent research paints a generally constructive picture on AbbVie, with most price target revisions skewing higher even as some firms move to the sidelines.분석 기사 • Dec 02
AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73
The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.73 on the 17th of...내러티브 업데이트 • Nov 23
ABBV: Future Performance Will Depend On Pipeline Expansion And Patent Protections
AbbVie’s analyst price target has increased modestly from $241.29 to $243.55. Analysts cite resilient performance in immunology products, extended Rinvoq exclusivity, and improving fundamentals as key drivers of sentiment.분석 기사 • Nov 18
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.73 on the 17th of...내러티브 업데이트 • Nov 08
ABBV: Future Performance Will Reflect Balance Between Patent Wins and Product Pressures
AbbVie's analyst price target has risen modestly from $237.48 to $241.29. Analysts cite resilient fundamentals and long-term patent settlements, which help offset recent industry downgrades and softer performance in some business units.내러티브 업데이트 • Oct 25
Continued Expansion in Neuroscience and Immunology Will Drive Leadership Beyond 2025
AbbVie's analyst price target has been raised from approximately $233 to $237 per share. Analysts cite ongoing revenue growth, improved margins, and extended exclusivity for key products as the main drivers behind the upward revision.내러티브 업데이트 • Oct 11
Expanding Immunology And Neuroscience Will Reshape Global Healthcare
AbbVie's analyst price target has increased significantly, rising from $227 to $233 per share. Analysts cite recent positive developments in patent settlements and stronger-than-expected performance across key growth drivers as the main rationales.내러티브 업데이트 • Sep 27
Expanding Immunology And Neuroscience Will Reshape Global Healthcare
AbbVie’s consensus price target has been raised from $217.45 to $227.22, as analysts highlight the value added by the extended Rinvoq patent runway, top- and bottom-line beats, pipeline expansion through the Bretisilocin acquisition, and underappreciated royalty streams. Analyst Commentary Bullish analysts cite a substantial extension of Rinvoq’s U.S. patent runway through favorable settlement, delaying generic entry until 2037—4 years beyond prior expectations—and modeling this as adding $11-$24 per share in value.내러티브 업데이트 • Sep 12
Expanding Immunology And Neuroscience Will Reshape Global Healthcare
AbbVie's price target was raised to $217.45 as analysts cited the value impact of extended Rinvoq exclusivity from litigation settlement, strong Q2 results, and positive pipeline developments, outweighing near-term Aesthetics headwinds. Analyst Commentary Bullish analysts cite the settlement of litigation regarding generic Rinvoq, extending market exclusivity in the U.S. to 2037 and reducing threats from earlier-than-anticipated generic competition.이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 77,913 | 22,034 | 33,582 | 32,010 | 24 |
| 12/31/2027 | 72,644 | 19,308 | 32,541 | 29,282 | 28 |
| 12/31/2026 | 67,225 | 14,920 | 26,700 | 24,882 | 29 |
| 3/31/2026 | 62,819 | 3,595 | 19,980 | 21,224 | N/A |
| 12/31/2025 | 61,160 | 4,186 | 17,816 | 19,030 | N/A |
| 9/30/2025 | 59,644 | 2,348 | 19,684 | 20,860 | N/A |
| 6/30/2025 | 58,328 | 3,723 | 18,239 | 19,283 | N/A |
| 3/31/2025 | 57,367 | 4,155 | 15,385 | 16,401 | N/A |
| 12/31/2024 | 56,334 | 4,238 | 17,832 | 18,806 | N/A |
| 9/30/2024 | 55,533 | 5,081 | 15,623 | 16,511 | N/A |
| 6/30/2024 | 55,000 | 5,298 | 17,780 | 18,638 | N/A |
| 3/31/2024 | 54,403 | 5,951 | 21,891 | 22,686 | N/A |
| 12/31/2023 | 54,318 | 4,820 | 22,062 | 22,839 | N/A |
| 9/30/2023 | 55,138 | 6,471 | 24,729 | 25,514 | N/A |
| 6/30/2023 | 56,023 | 8,635 | 24,799 | 25,542 | N/A |
| 3/31/2023 | 56,741 | 7,535 | 23,520 | 24,228 | N/A |
| 12/31/2022 | 58,054 | 11,782 | 24,248 | 24,943 | N/A |
| 9/30/2022 | 57,819 | 13,343 | 21,921 | 22,590 | N/A |
| 6/30/2022 | 57,349 | 12,569 | 22,214 | 22,923 | N/A |
| 3/31/2022 | 56,725 | 12,407 | 22,047 | 22,808 | N/A |
| 12/31/2021 | 56,197 | 11,468 | 21,990 | 22,777 | N/A |
| 9/30/2021 | 55,169 | 7,465 | 21,677 | 22,556 | N/A |
| 6/30/2021 | 53,729 | 6,599 | 19,572 | 20,451 | N/A |
| 3/31/2021 | 50,195 | 5,092 | 17,789 | 18,650 | N/A |
| 12/31/2020 | 45,804 | 4,556 | 16,790 | 17,588 | N/A |
| 9/30/2020 | 40,650 | 7,324 | 15,327 | 16,009 | N/A |
| 6/30/2020 | 36,227 | 6,906 | 14,115 | 14,734 | N/A |
| 3/31/2020 | 34,057 | 8,395 | 13,552 | 14,122 | N/A |
| 12/31/2019 | 33,266 | 7,842 | N/A | 13,324 | N/A |
| 9/30/2019 | 32,867 | 3,232 | N/A | 13,441 | N/A |
| 6/30/2019 | 32,624 | 4,093 | N/A | 13,410 | N/A |
| 3/31/2019 | 32,647 | 5,333 | N/A | 13,799 | N/A |
| 12/31/2018 | 32,753 | 5,657 | N/A | 13,427 | N/A |
| 9/30/2018 | 32,187 | 7,531 | N/A | 12,619 | N/A |
| 6/30/2018 | 30,946 | 6,419 | N/A | 11,366 | N/A |
| 3/31/2018 | 29,612 | 6,352 | N/A | 10,503 | N/A |
| 12/31/2017 | 28,216 | 5,283 | N/A | 9,960 | N/A |
| 9/30/2017 | 27,273 | 6,615 | N/A | 8,917 | N/A |
| 6/30/2017 | 26,710 | 6,582 | N/A | 7,100 | N/A |
| 3/31/2017 | 26,218 | 6,278 | N/A | 7,015 | N/A |
| 12/31/2016 | 25,638 | 5,923 | N/A | 7,041 | N/A |
| 9/30/2016 | 25,242 | 6,048 | N/A | 7,463 | N/A |
| 6/30/2016 | 24,754 | 5,690 | N/A | 8,164 | N/A |
| 3/31/2016 | 23,777 | 5,448 | N/A | 8,078 | N/A |
| 12/31/2015 | 22,859 | 5,118 | N/A | 7,535 | N/A |
| 9/30/2015 | 21,911 | 2,790 | N/A | 4,994 | N/A |
| 6/30/2015 | 20,986 | 2,064 | N/A | 4,625 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: ABBV 의 연간 예상 수익 증가율(25.2%)이 saving rate(3.5%)보다 높습니다.
수익 vs 시장: ABBV 의 연간 수익(25.2%)이 US 시장(16.8%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 수익: ABBV 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.
수익 대 시장: ABBV 의 수익(연간 6.3%)이 US 시장(연간 11.6%)보다 느리게 성장할 것으로 예상됩니다.
고성장 매출: ABBV 의 수익(연간 6.3%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: ABBV의 자본 수익률은 3년 후 228.1%로 매우 높을 것으로 예상됩니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/20 04:23 |
| 종가 | 2026/05/20 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
AbbVie Inc.는 51명의 분석가가 다루고 있습니다. 이 중 29명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Luisa Hector | Berenberg |